Intelliseq Secures €4M
Intelliseq Secures €4M to Accelerate U.S. Expansion and Precision Genomics Innovation
Polish biotech company Intelliseq, a pioneer in automated genomic data analysis, has raised €4.5 million (PLN 19 million) in its latest funding round. The investment, led by Vinci HiTech, with participation from Unfold.vc and private investors including Tadeusz Wesołowski (founder of Prosper S.A.), marks a major milestone in Intelliseq’s global expansion strategy.
Enabling Next-Generation Genetic Diagnostics
Founded in 2014 by scientists Klaudia Szklarczyk-Smolana, Marcin Piechota, Michał Korostyński, and Sławomir Gołda, Intelliseq develops bioinformatics tools that automate the analysis and interpretation of DNA. Their solutions aim to accelerate diagnostics for complex diseases, answering the challenges faced by the estimated 350 million people worldwide living with rare genetic disorders.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
The company partners with global research institutions, laboratories, and tech firms to provide scalable tools for genomic diagnostics. Notable partnerships include:
Metrodora Institute (USA) – Specializing in multi-system disease diagnostics
PrecisionLife (UK) – Working on chronic fatigue syndrome and long COVID risk profiling
DNAnexus (USA) – Offering Intelliseq’s somatic cancer and hereditary disease analysis tools through a platform supporting major genomic databases such as the UK Biobank
“Genomics is still only scratching the surface of its potential,” said Dr. Klaudia Szklarczyk-Smolana, CEO of Intelliseq. “We see growing demand for bioinformatics solutions that enable personalized treatment, better drug compatibility, and scalable diagnostics—and that’s exactly where Intelliseq is headed.”
Funding to Drive U.S. Market Entry
The €4.5 million round was spearheaded by Vinci HiTech, a VC platform that manages three funds focused on high-growth Polish tech ventures. The participation of Unfold.vc and high-profile angel investors signals strong confidence in Intelliseq’s commercial potential.
“Our priority is the continued commercialization and global deployment of advanced genome analysis tools,” added Szklarczyk-Smolana. “With the U.S. molecular diagnostics market expanding rapidly, this funding will support our entry and position us at the forefront of personalized genomics.”
The investment will fund Intelliseq’s U.S. market expansion and support the development of new algorithms to predict disease risks—an essential step toward mainstreaming precision healthcare worldwide.
